Evidence map›Paper›PMID 40484639›Full record

ArticleThorax2025

Associations of interstitial lung disease subtype and CT pattern with lung function and survival.

John S Kim, Janelle Pugashetti, Shwu-Fan Ma, Yong Huang, Anna J Podolanczuk, David A Lynch, Andrea Oh, Josyf Mychaleckyj, Ani Manichaikul, Stephen Rich and 15 more

Abstract read
In one paragraph

Article in Thorax, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Mycophenolate and azathioprine in fibrotic interstitial lung disease.American journal of respiratory and critical care medicine · 2026
    Observational
  2. Review
  3. Review
  4. Prevalence and Prognostic Impact of Progressive Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. From Chaos to Clarity: Reassessing Interstitial Lung Disease Terminology.American journal of respiratory and critical care medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

John S KimDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA jk6jb@uvahealth.org.ORCID 0000-0002-8887-150X
Janelle PugashettiDepartment of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Shwu-Fan MaDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Yong HuangDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Anna J PodolanczukDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.ORCID 0000-0002-9559-1485
David A LynchRadiology, National Jewish Health, Denver, Colorado, USA.ORCID 0000-0002-6329-2325
Andrea OhDepartment of Radiology, University of California Los Angeles, Los Angeles, California, USA.
Josyf MychaleckyjDepartment of Genome Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Ani ManichaikulDepartment of Genome Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.ORCID 0000-0002-5998-795X
Stephen RichDepartment of Genome Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Felix ChuaDepartment of Respiratory Medicine, Royal Brompton Hospital, Guy's and St. Thomas's NHS Foundation Trust and National Heart and Lung Institute Imperial College London, London, UK.ORCID 0000-0001-7845-0173
Traci M AdamsDepartment of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Kevin R FlahertyDepartment of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Joyce S LeeDepartment of Medicine, University of Colorado, Denver, Colorado, USA.
Joseph A LaskyMedicine, Tulane University, New Olreans, Louisiana, USA.
Ganesh RaghuUniversity of Washington, Seattle, Washington, USA.
Susan MurrayBiostatistics, University of Michigan, Ann Arbor, Michigan, USA.
Catherine SpinoBiostatistics, University of Michigan, Ann Arbor, Michigan, USA.
Fernando J MartinezDepartment of Medicine, University of Massachusetts Chan Medical School-UMass Memorial Health System, Worcester, Massachusetts, USA.
Imre NothDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Stephen M HumphriesRadiology, National Jewish Health, Denver, Colorado, USA.ORCID 0000-0002-5113-4530
Ayodeji AdegunsoyePulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois, USA.ORCID 0000-0002-7015-9610
Philip L MolyneauxDepartment of Respiratory Medicine, Royal Brompton Hospital, Guy's and St. Thomas's NHS Foundation Trust and National Heart and Lung Institute Imperial College London, London, UK.ORCID 0000-0003-1301-8800
Justin M OldhamDepartment of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Chad A NewtonDepartment of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-5256-9029

Funding

Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression TrajectoryR01HL169166 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2023 to 2026
$2.7M
Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung DiseaseR01HL166290 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2024 to 2026
$2.2M
Molecular Markers of Idiopathic Pulmonary Fibrosis ProgressionK23HL148498 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI NEWTON, CHAD ALAN · 2020 to 2024
$891k
Role of polyunsaturated fatty acids in pulmonary fibrosisK23HL150301 · NHLBI · UNIVERSITY OF VIRGINIA · PI KIM, JOHN S · 2021 to 2025
$858k
Improving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810k
A Multi-Dimensional Signature to Predict Treatment Failure in Patients with Connective Tissue Disease-Associated Interstitial Lung DiseaseK23HL171871 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Janelle Vu Pugashetti · 2025 to 2026
$392k
Impact of mechanical stretch on the progression of pulmonary fibrosis in mouse bleomycin modelR03AG085239 · NIA · UNIVERSITY OF VIRGINIA · PI HUANG, YONG · 2024 to 2024
$158k
NHLBI NIH HHS K23 HL146942NHLBI NIH HHS K23 HL148498NHLBI NIH HHS K23 HL150301NHLBI NIH HHS K23 HL171871NHLBI NIH HHS L30 HL181822NHLBI NIH HHS R01 HL166290NHLBI NIH HHS R01 HL169166NIA NIH HHS R03 AG085239
6 · The paper itself

Abstract

backgroundPrior work suggests different interstitial lung diseases (ILDs) that share the radiological usual interstitial pneumonia (UIP) pattern have an overall worse prognosis. However, epidemiological data with longitudinal sampling and replication remains lacking.

methodsData was used from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR) (n=932) and a meta-cohort of ILD research studies (n=1579). Linear mixed-effects models and Cox proportional hazard models were used to determine forced vital capacity (FVC) slopes and 5-year transplant-free survival, respectively, by ILD diagnosis and UIP radiological pattern. Secondarily, we examined FVC and survival by diagnosis and radiological fibrosis quantified by data-driven texture analysis (DTA) in the PFF-PR. Models were adjusted for age, sex, smoking and antifibrotic and immunosuppression medication use.

resultsThe proportions of idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (FHP) and connective tissue disease (CTD)-ILD were the following for PFF-PR (70%, 11%, 19%) and meta-cohort (21%, 32%, 47%). In the PFF-PR, CTD-ILD with UIP CT pattern was associated with slower FVC decline (-34.4 mL/year) compared with IPF (-158.4 mL/year) and longer transplant-free survival (HR 0.50, 95% CI 0.29 to 0.85). This was replicated in the meta cohort for FVC (-53.1 vs -185.9 mL/year, p<0.0001) and survival (HR 0.38, 95% CI 0.27 to 0.53). A similar pattern was seen using DTA to objectively categorise patients into higher and lower radiological fibrosis. Between IPF and FHP-UIP, FVC decline was not significantly different in the PFF-PR (-203.4 vs -158.4 mL/year, p=0.58) and meta-cohort (-124.0 vs -185.9 mL/year, p=0.25).

conclusionsEven in the presence of a UIP CT pattern, there may still be differences in lung function over time and survival, particularly for CTD-ILD.

Indexed as

LungLung Diseases, InterstitialTomography, X-Ray ComputedAgedFemaleHumansIdiopathic Pulmonary FibrosisMaleMiddle AgedPrognosisRegistriesSurvival RateVital CapacityIdiopathic pulmonary fibrosisImaging/CT MRI etcInterstitial Fibrosis

Identifiers

PMID40484639
PMCPMC12354206

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.